Deutsche Bank AG Has $2.03 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Deutsche Bank AG significantly increased its stake in Aurinia Pharmaceuticals by 76.7%, owning 252,446 shares worth approximately $2.03 million as of its latest SEC filing.
• Aurinia Pharmaceuticals reported an earnings per share (EPS) of $0.16 for the last quarter, missing the consensus estimate of $0.17, while revenue reached $70.01 million.
• Research analysts currently have a consensus rating of "Buy" for Aurinia Pharmaceuticals, with price targets ranging from $9.00 to $17.00.

Deutsche Bank AG grew its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 76.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 252,446 shares of the biotechnology company's stock after purchasing an additional 109,577 shares during the quarter. Deutsche Bank AG owned 0.18% of Aurinia Pharmaceuticals worth $2,030,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of AUPH. LPL Financial LLC increased its position in shares of Aurinia Pharmaceuticals by 21.8% during the 4th quarter. LPL Financial LLC now owns 46,600 shares of the biotechnology company's stock valued at $418,000 after purchasing an additional 8,327 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Aurinia Pharmaceuticals by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 72,084 shares of the biotechnology company's stock worth $647,000 after acquiring an additional 8,996 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Aurinia Pharmaceuticals by 1.0% in the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock worth $1,294,000 after acquiring an additional 1,421 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth $215,000. Finally, Barclays PLC grew its holdings in shares of Aurinia Pharmaceuticals by 11.2% in the 4th quarter. Barclays PLC now owns 243,948 shares of the biotechnology company's stock worth $2,190,000 after acquiring an additional 24,617 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada lifted their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $12.00.

Insider Transactions at Aurinia Pharmaceuticals

In other news, Director Kevin Tang acquired 200,000 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Tuesday, August 5th. The stock was purchased at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the transaction, the director owned 11,329,500 shares in the company, valued at approximately $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 1,300,000 shares of company stock worth $13,590,000 over the last ninety days. 12.20% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Stock Down 0.8%

Shares of Aurinia Pharmaceuticals stock traded down $0.10 during midday trading on Wednesday, hitting $12.11. The company's stock had a trading volume of 881,632 shares, compared to its average volume of 2,918,983. The firm has a market capitalization of $1.59 billion, a P/E ratio of 28.16 and a beta of 1.23. The stock has a 50-day simple moving average of $9.73 and a 200-day simple moving average of $8.61. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 1-year low of $6.42 and a 1-year high of $12.53.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.